This webinar has concluded — a recording is available
A recording of this webinar can be accessed on BCPhA’s e-learning platform.
Members can access for free on our eTraining Portal.
Binge eating disorder (BED) was first recognized as a distinct disorder by the American Psychiatric Association in 2013. Studies have shown that up to 30% obese individuals seeking treatment have BED or subclinical BED. The BC Pharmacy Association will be hosting a webinar on binge eating disorder in diabesity on February 3, 2021 and will discuss the prevalence and pathophysiology, diagnostic criteria and impact of BED.
Learning objectives
After participating in this webinar, participants will be better able to:
- Understand the prevalence and pathophysiology of BED
- Describe the diagnostic criteria and risk factors for binge eating disorder (BED)
- Identify patients who should be screened for BED
- Recognize the impact of BED on metabolic syndrome
About the Speaker: Dr. James W. Kim, MBBCh, PgDip(Diabetes)
Dr Kim is a general practitioner in Calgary with special interest in chronic disease, especially in diabetes and chronic migraine. He is a clinical assistant professor in the Department of Family Medicine at University of Calgary.
After graduating from his medical school in South Africa, he has completed post- graduate diploma in Diabetes in 2012 and works as a peer reviewer and editorial board member for numerous medical journals including Canadian Journal of Diabetes. He has also given numerous presentations locally and nationally including Family Medicine Forum, on the topics of diabetes, chronic migraine, binge eating disorder, ADHD, and respiratory medicine. He has also been involved in numerous CME slide deck development.
Within Diabetes Canada, his role includes steering committee member for the Clinical Practice Guideline, current co-chair of Primary Care Special Interest Group, Dissemination and Implementation member and has been a scientific planning committee member for the Annual Diabetes Canada Conference.
He is currently involved with PIONEER REAL research data with Novo Nordisk as the site lead investigator.